CLARITEV CORP (CTEV) Stock Fundamental Analysis
NYSE:CTEV - New York Stock Exchange, Inc. - US62548M2098 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to CTEV. CTEV was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of CTEV have multiple concerns. CTEV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CTEV has reported negative net income.
CTEV had a positive operating cash flow in the past year.
CTEV had negative earnings in 4 of the past 5 years.
In the past 5 years CTEV always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -23.16%, CTEV perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
The Return On Equity of CTEV (-7942.40%) is worse than 88.57% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.23%, CTEV is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
CTEV had an Average Return On Invested Capital over the past 3 years of 2.41%. This is below the industry average of 7.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.16% | ||
| ROE | -7942.4% | ||
| ROIC | 1.23% |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
1.3 Margins
The Operating Margin of CTEV (8.20%) is better than 82.86% of its industry peers.
CTEV's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 74.15%, CTEV is doing good in the industry, outperforming 80.00% of the companies in the same industry.
CTEV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | 74.15% |
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CTEV is destroying value.
The number of shares outstanding for CTEV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, CTEV has less shares outstanding
CTEV has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.24, we must say that CTEV is in the distress zone and has some risk of bankruptcy.
CTEV has a Altman-Z score (-0.24) which is in line with its industry peers.
CTEV has a Debt/Equity ratio of 310.26. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CTEV (310.26) is worse than 88.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 310.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.24 |
ROIC/WACC0.16
WACC7.65%
2.3 Liquidity
A Current Ratio of 1.02 indicates that CTEV should not have too much problems paying its short term obligations.
CTEV has a worse Current ratio (1.02) than 74.29% of its industry peers.
A Quick Ratio of 1.02 indicates that CTEV should not have too much problems paying its short term obligations.
The Quick ratio of CTEV (1.02) is worse than 74.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The earnings per share for CTEV have decreased by -0.25% in the last year.
Looking at the last year, CTEV shows a decrease in Revenue. The Revenue has decreased by -3.21% in the last year.
The Revenue has been decreasing by -1.09% on average over the past years.
EPS 1Y (TTM)-0.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.3%
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%3.47%
3.2 Future
CTEV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.28% yearly.
The Revenue is expected to grow by 2.81% on average over the next years.
EPS Next Y77.36%
EPS Next 2Y35.44%
EPS Next 3Y22.28%
EPS Next 5YN/A
Revenue Next Year0.16%
Revenue Next 2Y1.63%
Revenue Next 3Y2.81%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CTEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTEV indicates a somewhat cheap valuation: CTEV is cheaper than 80.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.16 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTEV's earnings are expected to grow with 22.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.44%
EPS Next 3Y22.28%
5. Dividend
5.1 Amount
CTEV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
71.61
+3.8 (+5.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners35.53%
Inst Owner ChangeN/A
Ins Owners8.14%
Ins Owner Change27.57%
Market Cap1.18B
Analysts80
Price Target40.46 (-43.5%)
Short Float %11.18%
Short Ratio6.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.46%
Min EPS beat(2)-23.58%
Max EPS beat(2)14.65%
EPS beat(4)1
Avg EPS beat(4)-387.47%
Min EPS beat(4)-1467.36%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-184.38%
EPS beat(12)5
Avg EPS beat(12)-291.62%
EPS beat(16)8
Avg EPS beat(16)-195.66%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)1.86%
Revenue beat(4)1
Avg Revenue beat(4)-2.8%
Min Revenue beat(4)-6.88%
Max Revenue beat(4)1.86%
Revenue beat(8)2
Avg Revenue beat(8)-2.49%
Revenue beat(12)3
Avg Revenue beat(12)-3.1%
Revenue beat(16)6
Avg Revenue beat(16)-1.91%
PT rev (1m)26.6%
PT rev (3m)83.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.79%
EPS NY rev (1m)0%
EPS NY rev (3m)-56.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.27 | ||
| P/FCF | N/A | ||
| P/OCF | 42.36 | ||
| P/B | 79.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.16 |
EPS(TTM)-40.5
EYN/A
EPS(NY)-11.53
Fwd EYN/A
FCF(TTM)-5.99
FCFYN/A
OCF(TTM)1.69
OCFY2.36%
SpS56.31
BVpS0.9
TBVpS-274.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.16% | ||
| ROE | -7942.4% | ||
| ROCE | 1.55% | ||
| ROIC | 1.23% | ||
| ROICexc | 1.23% | ||
| ROICexgc | 17.81% | ||
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | 74.15% | ||
| FCFM | N/A |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexcg growth 3Y-40.96%
ROICexcg growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score4
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 310.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 28.67% | ||
| Cap/Sales | 13.63% | ||
| Interest Coverage | 0.23 | ||
| Cash Conversion | 5.38% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -0.24 |
F-Score4
WACC7.65%
ROIC/WACC0.16
Cap/Depr(3y)24.85%
Cap/Depr(5y)22.67%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.3%
EPS Next Y77.36%
EPS Next 2Y35.44%
EPS Next 3Y22.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%3.47%
Revenue Next Year0.16%
Revenue Next 2Y1.63%
Revenue Next 3Y2.81%
Revenue Next 5YN/A
EBIT growth 1Y-50.8%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.04%
EBIT Next 3Y35.48%
EBIT Next 5YN/A
FCF growth 1Y-164.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.48%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%